125 related articles for article (PubMed ID: 21555331)
1. Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety.
Bailey JE; Papadopoulos A; Diaper A; Phillips S; Schmidt M; van der Ark P; Dourish CT; Dawson GR; Nutt DJ
J Psychopharmacol; 2011 Sep; 25(9):1199-206. PubMed ID: 21555331
[TBL] [Abstract][Full Text] [Related]
2. The effects of single dose anxiolytic medication on the CO2 models of anxiety: differentiation of subjective and objective measures.
Papadopoulos A; Rich A; Nutt DJ; Bailey JE
J Psychopharmacol; 2010 May; 24(5):649-56. PubMed ID: 18832434
[TBL] [Abstract][Full Text] [Related]
3. The effect of a clinically effective and non-effective dose of lorazepam on 7.5% CO₂-induced anxiety.
Diaper A; Papadopoulos A; Rich AS; Dawson GR; Dourish CT; Nutt DJ; Bailey JE
Hum Psychopharmacol; 2012 Nov; 27(6):540-8. PubMed ID: 23027657
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety.
Bailey JE; Papadopoulos A; Seddon K; Nutt DJ
J Psychopharmacol; 2009 Mar; 23(2):117-22. PubMed ID: 18562427
[TBL] [Abstract][Full Text] [Related]
5. Oxytocin interference in the effects induced by inhalation of 7.5% CO(2) in healthy volunteers.
de Oliveira DC; Chagas MH; Garcia LV; Crippa JA; Zuardi AW
Hum Psychopharmacol; 2012 Jul; 27(4):378-85. PubMed ID: 22711428
[TBL] [Abstract][Full Text] [Related]
6. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.
Coric V; Feldman HH; Oren DA; Shekhar A; Pultz J; Dockens RC; Wu X; Gentile KA; Huang SP; Emison E; Delmonte T; D'Souza BB; Zimbroff DL; Grebb JA; Goddard AW; Stock EG
Depress Anxiety; 2010 May; 27(5):417-25. PubMed ID: 20455246
[TBL] [Abstract][Full Text] [Related]
7. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF
J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750
[TBL] [Abstract][Full Text] [Related]
8. Serotonin regulation of the human stress response.
Hood SD; Hince DA; Robinson H; Cirillo M; Christmas D; Kaye JM
Psychoneuroendocrinology; 2006 Oct; 31(9):1087-97. PubMed ID: 16962720
[TBL] [Abstract][Full Text] [Related]
9. GABA-A receptors and the response to CO(2) inhalation - a translational trans-species model of anxiety?
Bailey JE; Nutt DJ
Pharmacol Biochem Behav; 2008 Jul; 90(1):51-7. PubMed ID: 18485466
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic.
Diaper A; Osman-Hicks V; Rich AS; Craig K; Dourish CT; Dawson GR; Nutt DJ; Bailey JE
J Psychopharmacol; 2013 Feb; 27(2):135-45. PubMed ID: 22516666
[TBL] [Abstract][Full Text] [Related]
11. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat.
Arborelius L; Skelton KH; Thrivikraman KV; Plotsky PM; Schulz DW; Owens MJ
J Pharmacol Exp Ther; 2000 Aug; 294(2):588-97. PubMed ID: 10900236
[TBL] [Abstract][Full Text] [Related]
12. The CRF(1) receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats.
McElroy JF; Ward KA; Zeller KL; Jones KW; Gilligan PJ; He L; Lelas S
Psychopharmacology (Berl); 2002 Dec; 165(1):86-92. PubMed ID: 12474122
[TBL] [Abstract][Full Text] [Related]
13. Effects of 7.5% CO2 challenge in generalized anxiety disorder.
Seddon K; Morris K; Bailey J; Potokar J; Rich A; Wilson S; Bettica P; Nutt DJ
J Psychopharmacol; 2011 Jan; 25(1):43-51. PubMed ID: 20233897
[TBL] [Abstract][Full Text] [Related]
14. Safety of ipsapirone treatment compared with lorazepam: discontinuation effects.
Busto UE; Naranjo CA; Bremner KE; Peachey JE; Bologa M
J Psychiatry Neurosci; 1998 Jan; 23(1):35-44. PubMed ID: 9505058
[TBL] [Abstract][Full Text] [Related]
15. 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
Gilligan PJ; He L; Clarke T; Tivitmahaisoon P; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy J; Ward K; Shen H; Wong H; Grossman S; Nemeth G; Zaczek R; Arneric SP; Hartig P; Robertson DW; Trainor G
J Med Chem; 2009 May; 52(9):3073-83. PubMed ID: 19361210
[TBL] [Abstract][Full Text] [Related]
16. Effects of lorazepam on brain activity pattern during an anxiety symptom provocation challenge.
Schunck T; Mathis A; Erb G; Namer IJ; Demazières A; Luthringer R
J Psychopharmacol; 2010 May; 24(5):701-8. PubMed ID: 19460871
[TBL] [Abstract][Full Text] [Related]
17. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
Cutler NR; Sramek JJ; Keppel Hesselink JM; Krol A; Roeschen J; Rickels K; Schweizer E
J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097
[TBL] [Abstract][Full Text] [Related]
19. [New anxiolytic drugs: methodological issues].
Ginestet D; Corruble E
Encephale; 1993; 19(6):627-37. PubMed ID: 12404782
[TBL] [Abstract][Full Text] [Related]
20. Reversal by quercetin of corticotrophin releasing factor induced anxiety- and depression-like effect in mice.
Bhutada P; Mundhada Y; Bansod K; Ubgade A; Quazi M; Umathe S; Mundhada D
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):955-60. PubMed ID: 20447436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
